MENOGARIL IN THE TREATMENT OF RELAPSED MULTIPLE-MYELOMA - A PHASE-II TRIAL OF THE CANCER CENTER OF WAKE-FOREST-UNIVERSITY

被引：1

作者：

CRUZ, JM ^{[1
]}

CASE, LD ^{[1
]}

DALTON, HB ^{[1
]}

RAMSEUR, WL ^{[1
]}

RICHARDS, F ^{[1
]}

JACKSON, DV ^{[1
]}

MUSS, HB ^{[1
]}

ZEKAN, PJ ^{[1
]}

BRODKIN, RA ^{[1
]}

BROWN, RC ^{[1
]}

HERRING, WB ^{[1
]}

LUSK, JA ^{[1
]}

OROURKE, MA ^{[1
]}

REDDY, SM ^{[1
]}

CAPIZZI, RL ^{[1
]}

机构：

[1] WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27103

来源：

INVESTIGATIONAL NEW DRUGS | 1992年 / 10卷 / 01期

关键词：

MENOGARIL; MULTIPLE MYELOMA;

D O I：

10.1007/BF01275478

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fifteen patients with relapsed multiple myeloma (MM) were treated with menogaril 160 mg/m2 intravenously (IV) every 28 days. No responses were seen: 8 patients had stable disease, 4 progressed after one course of therapy, and 3 patients were removed from study after 1 course for other reasons. Four of the 8 patients with stable disease had an improved performance status, and 3 had a decrease in analgesic use. The major toxicity was myelosuppression. The median progression-free interval was 3.0 months with a range of 0.7 to 22 months and median survival was 11.3 months with a range of 0.7 to 39 + months. Menogaril displays little activity in patients with previously treated MM.

引用

页码：35 / 37

页数：3

共 50 条

[31] A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma
Glasmacher, A
Hahn, C
Hoffmann, F
Naumann, R
Goldschmidt, H
Lilienfeld-Toal, M
Orlopp, K
Schmidt-Wolf, I
Gorschlüter, M
BRITISH JOURNAL OF HAEMATOLOGY, 2006, 132 (05) : 584 - 593
[32] A PHASE-II TRIAL OF GOSERELIN (ZOLADEX) IN RELAPSED EPITHELIAL OVARIAN-CANCER
CANTWELL, BMJ
LIND, MJ
MILLWARD, MJ
CARMICHAEL, J
HARRIS, AL
EUROPEAN JOURNAL OF CANCER, 1990, 26 (02) : 191 - 191
[33] A phase II trial of thalidomide in the treatment of relapsed multiple myeloma (MM) with laboratory correlative studies.
Rajkumar, SV
Fonseca, R
Dispenzieri, A
Lacy, MQ
Geyer, S
Wellik, L
Hayman, S
Lust, JA
Kyle, RA
Greipp, PR
Gertz, MA
Witzig, TE
BLOOD, 2000, 96 (11) : 168A - 168A
[34] PHASE-II TRIAL OF PIPERAZINEDIONE IN HODGKINS-DISEASE, NON-HODGKINS LYMPHOMA, AND MULTIPLE-MYELOMA - SOUTHWEST ONCOLOGY GROUP STUDY
JONES, SE
TUCKER, WG
HAUT, A
TRANUM, BL
VAUGHN, C
CHASE, EM
DURIE, BGM
CANCER TREATMENT REPORTS, 1977, 61 (09): : 1617 - 1621
[35] Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma
Ghobrial, Irene M.
Laubach, Jacob P.
Shain, Kenneth H.
Baz, Rachid
Boswell, Erica N.
Henrick, Patrick M.
Azab, Abdel Kareem
Hanlon, Courtney
Chuma, Stacey
Leblebjian, Houry
Noonan, Kimberly
MacNabb, Megan H.
Warren, Diane
Armand, Philippe
Paba-Prada, Claudia E.
Munshi, Nikhil C.
Schlossman, Robert L.
Anderson, Kenneth C.
Richardson, Paul G.
BLOOD, 2014, 124 (21)
[36] Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma
Ghobrial, Irene M.
Shain, Kenneth
Hanlon, Courtney
Banwait, Ranjit
Azab, Abdel Kareem
Laubach, Jacob P.
Armand, Philippe
Munshi, Nikhil C.
Schlossman, Robert L.
Chuma, Stacey
Boswell, Erica N.
Mostyn, Patrick
Houry, Leblebjian
Anderson, Kenneth C.
Richardson, Paul G.
BLOOD, 2013, 122 (21)
[37] PHASE-II TRIAL OF PEPLOMYCIN TREATMENT FOR PROSTATIC-CANCER
GARCIAGIRALT, E
GUINET, F
POUILLART, P
KERBRAT, P
GEDOUIN, D
ALLAIN, YM
FUMOLEAU, P
BULLETIN DU CANCER, 1986, 73 (01) : 91 - 92
[38] A PHASE-II TRIAL OF AMYGDALIN (LAETRILE) IN THE TREATMENT OF HUMAN CANCER
MOERTEL, C
RUBIN, J
SARNA, G
YOUNG, C
JONES, S
FLEMING, T
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 383 - 383
[39] Ixazomib in Combination With Thalidomide and Dexamethasone as Treatment for Patients With Relapsed/Refractory Multiple Myeloma: An Ongoing Phase II Trial
Ludwig, Heinz
Lechner, Daniel
Gunsilius, Eberhard
Fridrik, Michael
Petzer, Andreas
Kuehr, Thomas
Knop, Stefan
Schreder, Martin
Weisel, Katja
Rauch, Elisabeth
Poenisch, Wolfram
Greil, Richard
Zojer, Niklas
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E75 - E75
[40] A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Schroeder, Mark A.
Fiala, Mark A.
Huselton, Eric
Cardone, Michael H.
Jaeger, Savina
Jean, Sae Rin
Shea, Kathryn
Ghobadi, Armin
Wildes, Tanya
Stocked-Goldstein, Keith E.
Vij, Ravi
CLINICAL CANCER RESEARCH, 2019, 25 (13) : 3776 - 3783

← 1 2 3 4 5 →